PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8871837-8	1996	Neutrophil stimulation by serum-treated zymosan, at the concentration of 0.3 mg/ml, induced a release of lysozyme that was significantly higher in patients with RA when compared to control subjects (p < 0.05), whereas zymosan-activated beta-glucuronidase secretion was similar in the two donor populations.	Zymosan	40-47	lysozyme	Homo sapiens	105-113	
9743814-9	1998	CS and its fractions inhibit the directional chemotaxis induced by zymosan-activated serum, are able to decrease the phagocytosis and the release of lysozyme induced by zymosan and to protect the plasma membrane from oxygen reactive species.	Zymosan	169-176	lysozyme	Homo sapiens	149-157	
8871837-8	1996	Neutrophil stimulation by serum-treated zymosan, at the concentration of 0.3 mg/ml, induced a release of lysozyme that was significantly higher in patients with RA when compared to control subjects (p < 0.05), whereas zymosan-activated beta-glucuronidase secretion was similar in the two donor populations.	Zymosan	221-228	lysozyme	Homo sapiens	105-113	
3570357-7	1987	Examination of lysosomal enzyme release showed that sCM enhanced the release of lysozyme and beta-glucuronidase induced by either FMLP/cytochalasin B or zymosan.	Zymosan	153-160	lysozyme	Homo sapiens	80-88	
3673588-1	1987	A selective zymosan-induced release of lysozyme from freshly prepared human blood granulocytes and monocytes was inhibited by indomethacin, sulindac, piroxicam and ibuprofen.	Zymosan	12-19	lysozyme	Homo sapiens	39-47	
3710563-2	1986	Stimulated release of lysozyme (from specific granules and azurophil granules) and beta-glucuronidase (from azurophil granules) in the presence of both FMLP and serum-activated zymosan was markedly reduced in patients with actively spreading guttate psoriatic lesions, in whom relapse of lesions lasted for less than 1 month and papules involved about 13-25% of skin surface.	Zymosan	177-184	lysozyme	Homo sapiens	22-30	
2421757-5	1986	Similarly, the release of the lysosomal enzymes, beta-glucuronidase and lysozyme, from neutrophils of the WAS patient in response to serum treated zymosan (Zx), f-met peptide, and A23187 was not significantly different from that of his parents and 13 normal donors.	Zymosan	147-154	lysozyme	Homo sapiens	72-80	
3804532-1	1986	Doxycycline inhibited the release of lysozyme from human granulocytes and monocytes exposed to non-opsonized zymosan particles.	Zymosan	109-116	lysozyme	Homo sapiens	37-45	
3804532-5	1986	The divalent cation chelator, EDTA, also reduced the release of lysozyme from leukocytes exposed to non-opsonized zymosan.	Zymosan	114-121	lysozyme	Homo sapiens	64-72	
2982389-1	1985	Myeloperoxidase (MPO)-deficient neutrophils (PMN) released considerably more beta-glucuronidase, lysozyme and vitamin B12-binding activities, when exposed to opsonized zymosan (STZ), than the normal counterpart.	Zymosan	168-175	lysozyme	Homo sapiens	97-105	
6327867-1	1984	When exposed to zymosan or latex particles or heat-inactivated staphylococci, freshly prepared human blood monocytes and granulocytes rapidly released a large fraction of their lysozyme content.	Zymosan	16-23	lysozyme	Homo sapiens	177-185